Clinical trials
Treatment Resistant Schizophrenia clinical trials
Below are recruiting treatment resistant schizophrenia clinical trials, each written for real people, not researchers. We’re tracking 71 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06599372Recruiting
TMS for resistant voices in schizophrenia
This trial tests if a non-invasive brain stimulation method called transcranial magnetic stimulation (TMS) can reduce stubborn auditory hallucinations (hearing voices) in people with schizophrenia who haven't improved enough with medication.
Neuilly-sur-MarneAges 18 years+ - NCT06518720RecruitingPhase 2
Psilocybin for Chronic Nerve Pain and Depression
This trial tests whether psilocybin (a psychedelic medication) can help people who have both chronic nerve pain and depression that hasn't responded to standard treatments. The goal is to see if it can reduce pain and improve mood.
Toronto, OntarioAges 18–65 - NCT07748091Recruiting
Brain wave and inflammation markers in shock therapy for depression
This study looks at brain wave patterns and markers of inflammation in people with depression that hasn't improved with other treatments and who are receiving electroconvulsive therapy (ECT, also known as shock therapy). The goal is to understand how these markers might relate to how well ECT works.
Istanbul, BakırköyAges 18–60 - NCT07603804Recruiting
Accelerated Brain Stimulation for Treatment-Resistant Depression
This study tests an accelerated form of iTBS (a non-invasive brain stimulation technique) for depression that hasn't improved with antidepressant medications. The goal is to help people with major depression who haven't responded adequately to at least one antidepressant drug.
IstanbulAges 18–65 - NCT07382596RecruitingPhase 4
Cervical injections for treatment-resistant PTSD
This study tests if injecting a sugar-water solution around neck nerves can help PTSD that hasn't improved with standard treatments. Half the participants get sugar-water, half get salt-water, and you'll be assigned to usual care for 3 months first.
Lexington, KentuckyAges 19–90 - NCT07284667RecruitingPhase 2
A new medicine for depression that hasn't improved with other treatments
This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.
Birmingham, AlabamaAges 18–65 - NCT07226232RecruitingPhase 3
Psilocybin for veterans with treatment-resistant depression
This study tests whether psilocybin (a psychedelic substance) can help veterans with depression that hasn't improved with standard treatments.
Birmingham, AlabamaAges 18–75 - NCT06278909Recruiting
Nerve stimulation for stubborn anxiety
This study tests a new, non-invasive treatment using mild electrical stimulation on a nerve in your face (trigeminal nerve) to help with anxiety that hasn't improved with other treatments. It aims to see if this approach is safe and helpful for people with generalized anxiety disorder who have not responded to standard medications.
Kingston, OntarioAges 18–65 - NCT06943573RecruitingPhase 2
Psilocybin therapy for bipolar ii depression
This study tests whether a psychedelic drug called psilocybin (the active ingredient in 'magic' mushrooms), combined with therapy, can help relieve depression in people with bipolar II disorder who haven't gotten better with other treatments. You'll receive the drug in a supervised setting and attend follow-up visits to see how it affects your mood.
Vancouver, British ColumbiaAges 19–65 - NCT06599099Recruiting
Deep brain stimulation for depression that hasn't responded to other treatments
This trial tests if deep brain stimulation (a surgical implant that sends gentle electrical pulses to a specific area of the brain) can help people with bipolar I disorder who are currently in a severe depressive episode and have not found relief from multiple treatments.
Boston, MassachusettsAges 22–64 - NCT06370988Recruiting
Theta-burst stimulation for bipolar depression
This study tests a type of brain stimulation (theta-burst TMS) to see if it helps improve depression in people with bipolar disorder. It might be a good option if you have tried medication but still feel depressed.
Toronto, OntarioAges 18–65 - NCT05418894Recruiting
Study brain signals and improve treatment-resistant depression
This trial studies how brain activity relates to feelings and depression, using brain electrodes to measure signals. It’s meant for people with long-lasting, treatment-resistant major depression who may need stimulation while continuing psychiatric care.
Houston, TexasAges 22–70 - NCT05905705Recruiting
ECT plus a sleep monitor for treatment-resistant depression
This study looks at how electroconvulsive therapy (ECT) affects brain activity and sleep patterns in people with difficult-to-treat depression. It uses a wearable sleep monitor (the Dreem device) to record sleep while you receive ECT.
St Louis, MissouriAges 21–65 - NCT05518578RecruitingPhase 2
Drug trial for hard-to-control focal epilepsy with brain scar
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
Jacksonville, FloridaAges 18–70 - NCT05393622Recruiting
Brain stimulation trial for severe, treatment-resistant depression
This study tests an implanted form of brain stimulation for people with severe depression that has not improved with multiple medication trials. If you qualify, you would have brain scans and surgery planning, then follow a treatment-and-safety plan for several months.
Boston, MassachusettsAges 21–80 - NCT03973268RecruitingPhase 1
Ketamine study to understand treatment response in hard-to-treat depression
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
Bethesda, MarylandAges 18–70 - NCT03320304Recruiting
VNS for long-term depression that hasn’t improved with treatment
This trial studies how well and how efficiently VNS therapy works for people with long-lasting or repeated major depression that hasn’t responded to enough antidepressant treatments. It may help patients who are already receiving depression treatment but are still struggling.
ViennaAges 18 years+ - NCT02122562RecruitingPhase 2
Ketamine treatment for depression that hasn’t responded to care
This Phase 2 study tests ketamine for people with major depression that hasn’t improved after at least one antidepressant. It aims to see whether ketamine can reduce depression symptoms during a current depressive episode.
Iowa City, IowaAges 18–55 - NCT06611592RecruitingPhase 2
Pramipexole for hard-to-treat OCD
This study tests if pramipexole can help people whose OCD hasn't improved with standard treatments like SSRIs or certain antipsychotics. You might qualify if standard therapies haven't worked for you.
BragaAges 18–64 - NCT07363577RecruitingPhase 3
Testing LB-102 for adults with acute schizophrenia
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
Bentonville, ArkansasAges 18–65 - NCT07777575RecruitingPhase 4
Exercise and medication for weight loss while preserving muscle
This study tests whether a type 2 diabetes medication (tirzepatide) combined with a supervised resistance training (weight lifting) program helps prevent muscle loss while losing weight. You will either receive the medication or a placebo, and all participants will follow a diet and exercise plan.
München, BavariaAges 18–60 - NCT07467993RecruitingPhase 2
Testing GXV813 for hospitalized adults with schizophrenia
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
Bentonville, ArkansasAges 18–65 - NCT06863350Recruiting
Closing a heart hole to treat drug-resistant epilepsy
This trial tests if closing a small hole in the heart (called a PFO) can reduce seizures in people whose epilepsy isn't controlled by medication. It might offer a new treatment option for those who have both drug-resistant epilepsy and this heart condition.
Chengdu, SichuanAges 18–60
Hear when a new Treatment Resistant Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for treatment resistant schizophrenia?
- Yes. Clin2 currently lists 71 recruiting treatment resistant schizophrenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a treatment resistant schizophrenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a treatment resistant schizophrenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.